Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study

Browse by...

Deposit

Highlights

More informations

Title		Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study
Authors		Beguelin, Charles Suter, Annatina Bernasconi, Enos Fehr, Jan Kovari, Helen Bucher, Heiner C Stoeckle, Marcel Cavassini, Mathias Rougemont, Mathieu Schmid, Patrick Wandeler, Gilles Rauch, Andri Calmy, Alexandra show all authors [1 - 13]
Published in		Liver International. 2018, vol. 38, no. 3, p. 424-431
Abstract		Hepatitis C virus (HCV) therapies with interferon-free second-generation direct-acting antivirals (DAAs) are highly effective and well tolerated. They have the potential to increase treatment eligibility and efficacy in HIV-infected patients. We assessed the impact of DAAs on treatment uptake and efficacy, as well as its impact on the burden of liver disease in the Swiss HIV Cohort Study (SHCS).
Identifiers		DOI: 10.1111/liv.13528 PMID: 28741901
Full text		Article (Published version) (429 Kb) - Limited access to UNIGE
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine
Research group		VIH/SIDA (930)
Citation (ISO format)		BEGUELIN, Charles et al. Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study. In: Liver International, 2018, vol. 38, n° 3, p. 424-431. doi: 10.1111/liv.13528 https://archive-ouverte.unige.ch/unige:115506